Survival impact and predictive factors of axillary recurrence after sentinel biopsy

European Journal of Cancer

Volumn 58, Issue , 2016, Pages 73-82

  Houvenaeghel, Gilles ^a,n,o   Classe, Jean Marc ^b   Garbay, Jean Rémy ^c   Giard, Sylvie ^d   Cohen, Monique ^a,n   Faure, Chistine ^e   Charytansky, Hélène ^f   Rouzier, Roman ^g   Daraï, Emile ^h   Hudry, Delphine ⁱ   Azuar, Pierre ^j   Villet, Richard ^k   Gimbergues, Pierre ^l   Tunon De Lara, Christine ^m   Martino, Marc ^a   Fraisse, Jean ⁱ   Dravet, François ^b   Chauvet, Marie Pierre ^d   Goncalves, Anthony ^a,n,o   Lambaudie, Eric ^a,n,o  

^a AIX MARSEILLE UNIVERSITY   (France)

^b Institut de Cancerologie de l'Quest Rene Gauducheau   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE OSCAR LAMBRET   (France)

^e CENTRE LÉON BÉRARD   (France)

^f INSTITUT CLAUDIUS REGAUD   (France)

^g CENTRE RENÉ HUGUENIN   (France)

^h HÔPITAL TENON   (France)

ⁱ CENTRE GEORGES FRANÇOIS LECLERC   (France)

^j Centre Hospitalier de Grasse   (France)

^k GROUPE HOSPITALIER DIACONESSES CROIX SAINT SIMON   (France)

^l CENTRE JEAN PERRIN   (France)

^m INSTITUT BERGONIÉ   (France)

ⁿ INSTITUT PAOLI CALMETTES   (France)

^o AIX MARSEILLE UNIVERSITY   (France)

more..

Author keywords

Axillary recurrence; Breast cancer; Predictive factors; Sentinel lymph node biopsy; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HORMONAL RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; AGED; ARTICLE; AXILLARY RECURRENCE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; SENTINEL LYMPH NODE BIOPSY; SENTINEL LYMPH NODE METASTASIS; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; ADVERSE EFFECTS; AXILLA; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; FRANCE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LYMPH NODE; LYMPH NODE METASTASIS; MASTECTOMY; MICROMETASTASIS; MORTALITY; MULTICENTER STUDY; ODDS RATIO; PATHOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; AXILLA; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; FRANCE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM MICROMETASTASIS; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY; TIME FACTORS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84960532283     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.01.019     Document Type: Article

References (42)

1. R. Rao, D. Euhus, H.G. Mayo, and C. Balch Axillary node interventions in breast cancer: a systematic review JAMA 310 2013 1385 1394
2. B.J. van Wely, F.J. van den Wildenberg, P. Gobardhan, T. van Dalen, I.H. Borel Rinkes, E.B. Theunissen, and et al. Axillary recurrences after sentinel lymph node biopsy: a multicentre analysis and follow-up of sentinel lymph node negative breast cancer patients Eur J Surg Oncol 38 2012 925 931
3. V. Galimberti, A. Manika, P. Maisonneuve, G. Corso, L. Salazar Moltrasio, M. Intra, and et al. Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease Eur J Surg Oncol 40 2014 1203 1208
4. U. Veronesi, G. Paganelli, G. Viale, A. Luini, S. Zurrida, V. Galimberti, and et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer New Engl J Med 349 2003 546 553
5. C.M. Rudenstam, D. Zahrieh, J.F. Forbes, D. Crivellari, S.B. Holmberg, P. Rey, and et al. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93 J Clin Oncol 24 2006 337 344
6. G. Martelli, P. Boracchi, M. De Palo, S. Pilotti, S. Oriana, R. Zucali, and et al. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up Annals Surg 242 2005 1 6 discussion 7-9
7. G. Zavagno, G.L. De Salvo, G. Scalco, F. Bozza, L. Barutta, P. Del Bianco, and et al. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the Sentinella/GIVOM trial Annals Surg 247 2008 207 213
8. M. Donker, G. van Tienhoven, M.E. Straver, P. Meijnen, C.J. van de Velde, R.E. Mansel, and et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial Lancet Oncol 15 2014 1303 1310
9. C.M. Francissen, P.J. Dings, T. van Dalen, L.J. Strobbe, H.W. van Laarhoven, and J.H. de Wilt Axillary recurrence after a tumor-positive sentinel lymph node biopsy without axillary treatment: a review of the literature Annals Surg Oncol 19 2012 4140 4149
10. K.Y. Bilimoria, D.J. Bentrem, N.M. Hansen, K.P. Bethke, A.W. Rademaker, C.Y. Ko, and et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer J Clin Oncol 27 2009 2946 2953
11. A.M. Naik, J. Fey, M. Gemignani, L. Montgomery, J. Petrek, E. Port, and et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures Annals Surg 240 2004 462 468 discussion 468-471
12. M. Yi, S.H. Giordano, F. Meric-Bernstam, E.A. Mittendorf, H.M. Kuerer, R.F. Hwang, and et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database Annals Surg Oncol 17 Suppl. 3 2010 343 351
13. V. Galimberti, B.F. Cole, S. Zurrida, G. Viale, A. Luini, P. Veronesi, and et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial Lancet Oncol 14 2013 297 305
14. B. Fisher, S. Anderson, J. Bryant, R.G. Margolese, M. Deutsch, E.R. Fisher, and et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer New Engl J Med 347 2002 1233 1241
15. C. Louis-Sylvestre, K. Clough, B. Asselain, J.R. Vilcoq, R.J. Salmon, F. Campana, and et al. Axillary treatment in conservative management of operable breast cancer: dissection or radiotherapy? Results of a randomized study with 15 years of follow-up J Clin Oncol 22 2004 97 101
16. U. Veronesi, R. Orecchia, S. Zurrida, V. Galimberti, A. Luini, P. Veronesi, and et al. Avoiding axillary dissection in breast cancer surgery: a randomized trial to assess the role of axillary radiotherapy Annals Oncol 16 2005 383 388
17. G. Martelli, R. Miceli, A. Costa, D. Coradini, S. Zurrida, D. Piromalli, and et al. Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: fifteen-year results of a prospective study Cancer 112 2008 481 488
18. K.S. Hughes, L.A. Schnaper, D. Berry, C. Cirrincione, B. McCormick, B. Shank, and et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer New Engl J Med 351 2004 971 977
19. R. Agresti, G. Martelli, M. Sandri, E. Tagliabue, M.L. Carcangiu, I. Maugeri, and et al. Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98) Cancer 120 2014 885 893
20. G. Canavese, A. Catturich, C. Vecchio, D. Tomei, M. Gipponi, G. Villa, and et al. Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of randomized trial Annals Oncol 20 2009 1001 1007
21. R.E. Mansel, L. Fallowfield, M. Kissin, A. Goyal, R.G. Newcombe, J.M. Dixon, and et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial J Natl Cancer Inst 98 2006 599 609
22. Z. Wang, L.C. Wu, and J.Q. Chen Sentinel lymph node biopsy compared with axillary lymph node dissection in early breast cancer: a meta-analysis Breast Cancer Res Treat 129 2011 675 689
23. N.S. Kapoor, M.S. Sim, J. Lin, and A.E. Giuliano Long-term outcome of patients managed with sentinel lymph node biopsy alone for node-negative invasive breast cancer Arch Surg 147 2012 1047 1052
24. M. Bortolini, F. Genta, C.P. Biacchiardi, E. Zanon, M. Camanni, and F. Deltetto Axillary dissection in breast cancer patients with metastatic sentinel node: to do or not to do? Suggestions from our series ISRN Oncol 2011 2011 527904
25. J. Park, J.V. Fey, A.M. Naik, P.I. Borgen, K.J. Van Zee, and H.S. Cody 3rd A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram Annals Surg 245 2007 462 468
26. A.E. Giuliano, L. McCall, P. Beitsch, P.W. Whitworth, P. Blumencranz, A.M. Leitch, and et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial Annals Surg 252 2010 426 432
27. E.J. Rutgers Sentinel node biopsy: interpretation and management of patients with immunohistochemistry-positive sentinel nodes and those with micrometastases J Clin Oncol 26 2008 698 702
28. V.P. Tjan-Heijnen, M.J. Pepels, and M. de Boer Impact of omission of completion axillary lymph node dissection (cALND) or axillary radiotherapy (ax RT) in breast cancer patients with micrometastases (pN1mi) or isolated tumor cells (pN0[i ?]) in the sentinel lymph node (SN): results from the MIRROR study ASCO, CRA 506, Edition 2009
29. M.J. Pepels, M. de Boer, P. Bult, J.A. van Dijck, C.H. van Deurzen, M.B. Menke-Pluymers, and et al. Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells Annals Surg 255 2012 116 121
30. M. Sola, J.A. Alberro, M. Fraile, P. Santesteban, M. Ramos, R. Fabregas, and et al. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000 Annals Surg Oncol 20 2013 120 127
31. M.J. Pepels, J.H. Vestjens, M. de Boer, M. Smidt, P.J. van Diest, G.F. Borm, and et al. Safety of avoiding routine use of axillary dissection in early stage breast cancer: a systematic review Breast Cancer Res Treat 125 2011 301 313
32. J.P. Bulte, B.J. van Wely, S. Kasper, G. Kuijt, F.J. van den Wildenberg, L.J. Strobbe, and et al. Long-term follow-up of axillary recurrences after negative sentinel lymph node biopsy: effect on prognosis and survival Breast Cancer Res Treat 140 2013 143 149
33. A.J. Lowery, M.R. Kell, R.W. Glynn, M.J. Kerin, and K.J. Sweeney Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype Breast Cancer Res Treat 133 2012 831 841
34. D.N. Krag, S.J. Anderson, T.B. Julian, A.M. Brown, S.P. Harlow, J.P. Costantino, and et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial Lancet Oncol 11 2010 927 933
35. B.G. Haffty, K.K. Hunt, J.R. Harris, and T.A. Buchholz Positive sentinel nodes without axillary dissection: implications for the radiation oncologist Journal Clin Oncol 29 2011 4479 4481
36. G.H. Lyman, A.E. Giuliano, M.R. Somerfield, A.B. Benson 3rd, D.C. Bodurka, H.J. Burstein, and et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer J Clin Oncol 23 2005 7703 7720
37. T.F. Tvedskov, M.B. Jensen, E. Balslev, and N. Kroman Robust and validated models to predict high risk of non-sentinel node metastases in breast cancer patients with micrometastases or isolated tumor cells in the sentinel node Acta Oncol 53 2014 209 215
38. T.F. Tvedskov, M.B. Jensen, I.M. Lisse, B. Ejlertsen, E. Balslev, N. Kroman, and et al. High risk of non-sentinel node metastases in a group of breast cancer patients with micrometastases in the sentinel node Int J Cancer 131 2012 2367 2375
39. W. Zhou, Z. He, J. Xue, M. Wang, X. Zha, L. Ling, and et al. Molecular subtype classification is a determinant of non-sentinel lymph node metastasis in breast cancer patients with positive sentinel lymph nodes PLoS One 7 2012 e35881
40. K. Gulben, U. Berberoglu, O. Aydogan, and V. Kinas Subtype is a predictive factor of nonsentinel lymph node involvement in sentinel node-positive breast cancer patients J Breast Cancer 17 2014 370 375
41. F. Reyal, C. Belichard, R. Rouzier, E. de Gournay, C. Senechal, F.C. Bidard, and et al. Non-sentinel lymph node metastasis prediction in breast cancer with metastatic sentinel lymph node: impact of molecular subtypes classification PLoS One 7 2012 e47390
42. S. Aebi, S. Gelber, S.J. Anderson, I. Láng, A. Robidoux, M. Martín, and et al. Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial Lancet Oncol 15 2 2014 156 163